Title of Invention	PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF MYOCARDIAL DISEASES COMPRISING CILOBRADINE
Abstract	Pharmaceutical composition for the treatment of myocardial diseases accompanied by hypertrophy, comprising cilobradine and a pharmaceutical carrier or diluent, characterized in that the amount of cilobradine in the composition is between 0.2 and 8.8%.

Full Text

FORM 2 THE PATENTS ACT 1970 [39 OF 1970] & THE PATENTS RULES, 2003 COMPLETE SPECIFICATION [See Section 10; rule 13] "PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF MYOCARDIAL DISEASES COMPRISING CILOBRADINE" BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (formerly known as BOEHRINGER INGELHEIM PHARMA KG), a German company of Binger Strasse 173, D-55216 Ingelheim am Rhein, Germany, The following specification particularly describes the invention and the manner in which it is to be performed: The present invention relates to pharmaceutical composition for the treatment of myocardial diseases comprising cilobradine,. Elevated heart rate may be treated with'bradycardiac substances, particularly Ca++ channel blockers such as diltiazem and verapamil or beta-receptor blockers such as atenolol,, bisoprolol, carvedolol, metoprolol or tpropanolol and ±f channel blockers such as zatebradine [1- (7,8-dimethoxy-1,3 , 4, 5-tetrahydro-2H-3-benzazepin-2-on-3-yl) -3- [N--methyl-N-(2-(3,4-dimethoxy-phenyl)-ethyl)-propane] (see EP-B-0 065 229), 3-[(N-(2-(3,4-dimethoxy-phenyl)-ethyl)-piperidin-3-yl) -methyl] - (7, 8-dimethoxy-l, 3,4, 5-tetrahydro-2H-3-benzazepin-2-one (see EP-B-Q'224 794) and its enantiomers cilobradine [ (+)-3-[(N- (2-(3,4-dimethoxy-phenyl)-ethyl)- , piperidin-3- (S) -yl) -methyl] - (7, 8-dimethoxy-l, 3 , 4, 5-tetrahydro-2H-3-benzazepin-2-one] or alinidine [2-(N-allyl-2,6-dichloro-anilino)-2-imidazplidine), cf. also US Patent No. 3,708,485], while zatebradine is also known to have a favourable activity in the treatment of cardiac.insufficiency (see EP-B-0 471 388.) . Moreover it is known that bradycardiac substances, particularly the abovementioned compounds, of which the if channel blockers such as zatebradine, cilobradine or alinidine, and in particular cilobradine, are preferred, can have a beneficial effect on the symptoms of myocardial diseases accompanied by hypertrophy,'particularly for the treatment of idiopathic hypertrophic cardiomyopathies (HCM) such as hypertrophy of the remainder of the myocardium after myocardial infarction, ischaemic cardiomyopathy, hypertrophy of the myocardium in valve defects and myocarditis under toxic or iatrogenic influences. Surprisingly it has now been found that bradycardiac substances, of which the ifchannel blockers such as zatebradine, cilobradine or alinidine, and in particular cilobradine, are preferred, not only have a favourable effect on the clinical symptoms of hypertrophic cardiomyopathy, but will even induce regression of these serious heart diseases. The present invention thus relates to the new use of bradycardiac substances, particularly the abovementioned compounds, of which the if channel blockers such as zatebradine, cilobradine or alinidine, and in particular cilobradine, are preferred, to induce the regression of myocardial diseases accompanied by hypertrophy, particularly for the treatment of idiopathic hypertrophic cardiomyopathies (HCM) in humans and domestic pets. In order to achieve the effect according to the invention it is expedient to use the dosage known from the literature for the treatment of elevated heart rate for the individual bradycardiac substances. For example the single dose for cilobradine is 0.1 to 0.5 mg/kg per os, preferably 0.2 to .0.4 mg/kg, 1 to 3 x daily, for zatebradine it is 0.2 to.1 mg/kg 2 x daily and for alinidine it is 0.5 to 5 mg/kg 2 x daily. The new use of the bradycardiac substances according to the invention was investigated with the if channel blocker -cilobradine by way of example, using the following method: A cat with severe hypertrophic cardiomyopathy (heart rate about 200 beats/minute), ECG with ST accentuations as a sign of myocardial ischaemia, increased creatinine kinase activity in the plasma and in the ultrasound image, massive compression of the ventricular wall with a reduction in the ventricular volume and the ejection fraction, exhibited a significant improvement in clinical symptoms after treatment with the if channel blocker cilobradine (0.3 mg/kg per os, 2 x daily) (relief from pain, normal ECG, return of normal physiological activity pattern). Follow-up investigations after one year and after about 2 years' treatment surprisingly showed a regression in myocardial hypertrophy while the improvement in symptoms was maintained. The htypertrophic cardiomyopathy in the cat serves as a model for the corresponding disease in humans (Kittleson et al., Circulation 91, 3172-3180 (1999)). Treatment with the if channel blocker cilobradine thus leads not only to an improvement in symptoms but also to regression of the disease. The present invention also relates to drug combinations, containing at least one bradycardiac substance, particularly one of the abovementioned compounds, preferably an if channel blocker, and at least one cardioactive substance such as a cardioglycoside, e.g. methyldigoxin or digitoxin, a vasodilator, e.g. nitroglycerine, an ACE inhibitor, e.g. captopril or enalapril, an angiotensin-II antagonist, e.g. losartan or telmisartan, which are also suitable for treating myocardial diseases accompanied by hypertrophy, particularly for the treatment of idiopathic hypertrophic cardiomyopathies (HCM), if a rise in heart rate can be prevented by combining them with a bradycardiac substance. To achieve the effect according to the invention it is convenient to use the dosages known from the literature for-the individual bradycardiac substances for the treatment of elevated heart rate and the dosages known from the literature for the cardioactive compound used. For this purpose the bradycardiac substances, either on their own or combined with other cardioactive compounds, are formulated with one or more conventional inert carriers and/or diluents, e.g. with maize starch, lactose, glucose, microcrystalline cellulose, magnesium stearate, polyvinylpyrrolidone, citric acid, tartaric acid, water, water/ethanol, water/glycerol, water/sorbitol, water/polyethyleneglycol, propyleneglycol, stearyl alcohol, carboxymethylcellulose or fatty substances such as hard fat or suitable mixtures thereof, to produce conventional Galenic preparations such as plain or coated tablets, capsules, powders, suspensions, solutions, sprays or suppositories. Thus, for example, the combination consisting of cilobradine and a cardioactive compound conveniently contains 0.1 to 0.5 mg/kg, preferably'0.2 to 0.4 mg/kg of cilobradine per os plus 0.01 to 1 mg of methyldigoxin, 1 to 2 x daily, 0.01 to 1 mg of digoxin, 1 x daily, 0.1 to 2 mg of nitroglycerine, 2 to 3 x daily, 10 to 100 mg of captopril, 1 to 2 x daily, 2 to 20 mg of enalapril, 1 x daily, 10 to 200 mg of losartan, 2 x daily, or 20 to 80 mg of telmisartan, 1 x daily. As the partners for the if channel blockers in the drug combination additionally act on an independent biological system and if channel blockers inhibit reflex increases in heart rate, which may occur in connection with the above combination partner, these have a synergistic activity. The Examples that follow are intended to illustrate the invention without restricting it: Example 1 Capsules containing 1.25 mcr of cilobradine Composition: 1 capsule contains: lactose monohydrate 82.75 mg maize starch 55.3 mg Method of preparation The active substance, lactose monohydrate and maize starch are mixed and packed into size 4 capsules. Example 2 Capsules containing 10 mcr of cilobradine Composition: 1 capsule contains: lactose monohydrate 77.6 mg maize starch 51.7 mg Method of preparation The active substance, lactose monohydrate and maize starch are mixed and packed into size 4 capsules. Example 3 Tablets containing 7.5 mg of cilobradine Composition: 1 tablet contains: active substance 7.5 mg maize starch 59.5 mg lactose 48.0 mg polyvinylpyrrolidone 4.0 mg magnesium stearate 1.0 mg 120.0 mg Method of preparation The active substance, maize starch, lactose and polyvinylpyrrolidone are mixed and moistened with water. The moist mixture is forced through a sieve with a 1.5 mm mesh and dried at 45°C. The dry granules are passed through a sieve with a 1.0 mm mesh and mixed with magnesium stearate. The finished mixture is compressed in a tablet press with punches 7 mm in diameter provided with a dividing notch, to form tablets. Weight of tablet: 120 mg Example 4 Coated tablets containing 5 mg of cilobradine 1 tablet core contains: active substance 5.0 mg maize starch 41.5 mg lactose 30.0 mg polyvinylpyrrolidone 3 . 0 mg magnesium stearate 0.5 mg 8 0.0 mg Method of preparation The active substance, maize starch, lactose and polyvinylpyrrolidone are mixed thoroughly and moistened with water. The moist mass is forced through a sieve with a 1.0 mm mesh and dried at 45°C, then the granules are passed through the same sieve. After mixing with magnesium stearate, convex tablet cores with a diameter of 6 mm are compressed in a tablet-making machine. The tablet cores thus produced are -coated in known manner with a coated consisting essentially of sugar and talc. The finished coated tablets are polished with wax. Weight of coated tablet: 130 mg Example 5 Ampoules containing 5'mg.of cilobradine 1 ampoule contains: active substance 5.0 mg sorbitol -50.0 mg water for injections ad 2.0 mg Method of preparation In a suitable mixing vessel the active substance is dissolved in water for injections and the solution is made isotonic with sorbitol. After filtration through a diaphragm filter, the solution is transferred into purified and sterilised ampoules under N2 and autoclaved for 20 minutes in a stream of water vapour. Example 6 Suppositories containing 10 mg of cilobradine 1 suppository contains: active substance 0.010 g hard fat (e.g. Witepsol H 19 and "W 45) 1.690 g 1.700 g Method of preparation The hard fat is melted. At 3 8°C the ground active substance is homogeneously dispersed in the melt. This is cooled to 35°C and poured into slightly chilled suppository moulds. Example 7 Drops solution containing 10 mg of cilobradine 100 ml of solution contain: active substance ' 0.2 g hydroxyethylcellulose 0.15 g tartaric acid 0.1 g sorbitol solution, 70 % dry matter 30.0 g glycerol 10.0 g benzoic acid 0.15 g dist. water ad 100 ml Method of preparation The distilled water is heated to 70°C. The hydroxyethylcellulose, benzoic acid and tartaric acid are dissolved therein with stirring. The solution is cooled to ambient temperature and the glycerol and the sorbitol solution are added with stirring. At ambient temperature the active substance is added and the mixture is stirred to dissolve it completely. It is then evacuated with stirring to. eliminate air from the syrup. WE CLAIM: 1. Pharmaceutical composition for the treatment of myocardial diseases accompanied by hypertrophy, comprising cilobradine and a pharmaceutical carrier or diluent, characterized in that the amount of cilobradine in the composition is between 0.2 and 8.8%. 2. Pharmaceutical composition as claimed in claim 1, wherein it further contains an angiotensin-II antagonist in an amount comprised between 10 to 200 mg. 3. Pharmaceutical composition as claimed in claim 2, wherein the angiotensin-II antagonist is telmisartan and in that it is present in the composition in an amount comprised between 20 to 80 mg. Dated this 17th day of September, 2002. [DEEPAK MUNDRA] OF REMFRY & SAGAR ATTORNEY FOR THE APPLICANTS

Documents:

in-pct-2002-01274-mum-cancelled pages(14-11-2006).pdf

in-pct-2002-01274-mum-claims(granted)-(14-11-2006).doc

in-pct-2002-01274-mum-claims(granted)-(14-11-2006).pdf

in-pct-2002-01274-mum-correspondence(09-08-2007).pdf

IN-PCT-2002-01274-MUM-CORRESPONDENCE(26-3-2010).pdf

in-pct-2002-01274-mum-correspondence(ipo)-(22-08-2007).pdf

in-pct-2002-01274-mum-english translation(17-09-2002).pdf

in-pct-2002-01274-mum-form 13(05-05-2003).pdf

in-pct-2002-01274-mum-form 13(16-08-2007).pdf

in-pct-2002-01274-mum-form 18(30-11-2005).pdf

in-pct-2002-01274-mum-form 1a(14-11-2006).pdf

in-pct-2002-01274-mum-form 1a(16-08-2007).pdf

in-pct-2002-01274-mum-form 2(granted)-(14-11-2006).doc

in-pct-2002-01274-mum-form 2(granted)-(14-11-2006).pdf

IN-PCT-2002-01274-MUM-FORM 26(26-3-2010).pdf

in-pct-2002-01274-mum-form 3(14-11-2006).pdf

in-pct-2002-01274-mum-form 3(17-09-2002).pdf

in-pct-2002-01274-mum-form 5(17-09-2002).pdf

in-pct-2002-01274-mum-pct-ipea-409(17-09-2002).pdf

in-pct-2002-01274-mum-petition under rule 137(14-11-2006).pdf

in-pct-2002-01274-mum-petition under rule 138(14-11-2006).pdf

in-pct-2002-01274-mum-power of authority(14-11-2006).pdf

in-pct-2002-01274-mum-power of authority(17-09-2002).pdf